BFS
RAPP

Bare Financial Services’s Rapport Therapeutics RAPP Stock Holding History

Bare Financial Services’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63K Buy
+39
New +$1.43K ﹤0.01% 1192
2026
Q1 		– Sell
-16
Closed -$485 – 1905
2025
Q4 		$485 Buy
+16
New +$443 ﹤0.01% 1431

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Bare Financial Services's RAPP Position: Q2 2026 in Review

Bare Financial Services opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 39 shares worth $1.63K. The stake represents ﹤0.01% of the portfolio and ranks #1192 among its holdings. This is a return to the name: Bare Financial Services previously reported a position in RAPP as recently as Q4 2025.

Bare Financial Services first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Bare Financial Services held 39 shares of Rapport Therapeutics worth $1.63K as of Q2 2026.
  • Rapport Therapeutics was a new Bare Financial Services position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1192 holding.
  • Bare Financial Services first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.